TD-HV811016

Enavatuzumab(TD-HV811016) is a research-grade recombinant antibody targetingCD266. Produced in mammalian cells with native-like glycosylation.HighlightsResearch Grade— For PK/PD studies, assay development, and ADA research.Native Glycosylation— Mammalian expression ensures native-like patterns.

Human

ELISA, Bioactivity: FACS, Functional assay, Research in vivo

Humanized

IgG1-kappa

Monoclonal

FGF-inducible 14, TNFRSF12A, FN14, CD266, TweakR, Fibroblast growth factor-inducible immediate-early response protein 14, Tweak-receptor, Tumor necrosis factor receptor superfamily member 12A

Please contact the lab for this information.

>95% purity as determined by SDS-PAGE.

Protein A/G purified from cell culture supernatant.

Q9NP84

Liquid

0.01M PBS, pH 7.4.Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.

PDL192, 1062149-33-0

Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .• TWEAK/Fn14 signaling in tumors., PMID:28639899• The TWEAK/Fn14/CD163 axis-implications for metabolic disease., PMID:34542797• TWEAK/Fn14 axis in respiratory diseases., PMID:32526219• TWEAK/Fn14 signalling driven super-enhancer reprogramming promotes pro-metastatic metabolic rewiring in triple-negative breast cancer., PMID:38965263• Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (TWEAK)/Fibroblast Growth Factor-Inducible 14 (Fn14) Axis in Cardiovascular Diseases: Progress and Challenges., PMID:32053869• Role of the TWEAK/Fn14 pathway in autoimmune diseases., PMID:26659091• TWEAK/Fn14 signaling: a promising target in intervertebral disc degeneration., PMID:26907852• Controversies in TWEAK-Fn14 signaling in skeletal muscle atrophy and regeneration., PMID:32200423• Role of tumor necrosis factor-like weak inducer of apoptosis (TWEAK)/fibroblast growth factor-inducible 14 (Fn14) axis in rheumatic diseases., PMID:23106895• Tumor Necrosis Factor Receptor Mediates Fibroblast Growth Factor-Inducible 14 Signaling., PMID:28934756

SEC-HPLC detection for Research Grade Enavatuzumab.　　|　SDS-PAGE for Research Grade Enavatuzumab.　　|　Western blot analysis was performed using anti-CD266/TNFRSF12A monoclonal antibody at 1ug/mL on various samples.Lane 1:recombinant human CD266/TNFRSF12A (Catalog No:TD-HV811011)Lane 2:negative control

For research use only. Not suitable for clinical or therapeutic use.